French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday a strategic partnership with RadioMedix Inc and Orano Med to develop AlphaMedix, a promising radioligand therapy for rare cancers.
RadioMedix is a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in cancer. French clinical-stage biotechnology company Orano Med, a subsidiary of the Orano Group, is developing lead-212 (212Pb) radioligand therapies (RLTs) against cancer.
AlphaMedix (212Pb-DOTAMTATE) is currently being evaluated for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. AlphaMedix is a TAT which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. It recently received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for patients who are naïve to peptide-receptor radionuclide therapy.
Under the terms of the exclusive licensing agreement Sanofi will commercialise AlphaMedix globally, while Orano Med will manufacture the drug. RadioMedix and Orano Med will receive an upfront payment of EUR100m and up to EUR220m in milestone payments, as well as tiered royalties.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024